Ablation Reboots the Response in Advanced Hepatocellular Carcinoma With Stable or Atypical Response During PD-1 Therapy: A Proof-of-Concept Study
Ning Lyu, Yanan Kong, Xiaoxian Li, Luwen Mu, Haijing Deng, Huiming Chen, Meng He, Jinfa Lai, Jibin Li, Hailin Tang, Youen Lin, Ming Zhao, Ning Lyu, Yanan Kong, Xiaoxian Li, Luwen Mu, Haijing Deng, Huiming Chen, Meng He, Jinfa Lai, Jibin Li, Hailin Tang, Youen Lin, Ming Zhao
Abstract
Background: The anti-programmed cell death protein-1 (PD-1) inhibitor is one of the second-line therapies for advanced hepatocellular carcinoma (HCC) after sorafenib failure. The goal of this study is to evaluate the feasibility and safety of ablation on the tumor in patients with advanced HCC who had stable disease or atypical response during single anti-PD-1 therapy after sorafenib failure. Atypical response defined as mixed responses in different lesions of the same individual (e.g., active or stable lesions mixed with progressive lesions). Patients and Methods: This proof-of-concept clinical trial enrolled 50 patients treated with an anti-PD-1 inhibitor of nivolumab or pembrolizumab monotherapy between July 2015 and Nov 2017. Thirty-three cases with stable disease or atypical response to anti-PD-1 inhibitor received subtotal thermal ablation. The safety and the response of ablation during anti-PD-1 therapy were evaluated. The survival was estimated by the Kaplan-Meier curve. Results: Of all 50 patients treated with anti-PD-1 therapy, the rate of response, stable disease, atypical and typical progression were 10% (n = 5), 42% (n = 21) 32% (n = 16), and 12% (n = 6), respectively. Additional ablation improved efficacy with tolerable toxicity, and the response rate was increased from 10 to 24% (12/50). The median time to progression, progression-free survival, and overall survival was 6.1 months (95%CI, 2.6-11.2), 5 months (95%CI, 2.9-7.1), and 16.9 months (95%CI, 7.7-26.1), respectively. Conclusions: This proof-of-concept trial suggested that additional ablation may increase the objective response rate with tolerated toxicity and achieved a relatively better median survival, in advanced HCC patients who had stable or atypical progressive diseases during anti-PD-1 therapy, which may provide a potentially promising strategy to treat advanced HCC. Trial registration number: ClinicalTrials.gov identifier: NCT03939975.
Keywords: anti-PD-1 mAbs; hepatocellular carcinoma; nivolumab; pembrolizumab; thermal ablation.
Copyright © 2020 Lyu, Kong, Li, Mu, Deng, Chen, He, Lai, Li, Tang, Lin and Zhao.
Figures
References
- Villanueva A. Hepatocellular carcinoma. N Engl J Med. (2019) 380:1450–62. 10.1056/NEJMra1713263
- Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. . Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. (2020) 382:1894–905. 10.1056/NEJMoa1915745
- Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. . Lenvatinib vs. sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. (2018) 391:1163–73. 10.1016/S0140-6736(18)30207-1
- Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, et al. . Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. (2017) 389:56–66. 10.1016/S0140-6736(16)32453-9
- Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, et al. . Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. (2018) 379:54–63. 10.1056/NEJMoa1717002
- Zhu AX, Baron AD, Malfertheiner P, Kudo M, Kawazoe S, Pezet D, et al. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: analysis of reach trial results by child-pugh score. JAMA Oncol. (2017) 3:235–43. 10.1001/jamaoncol.2016.4115
- Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. (2019) 20:282–96. 10.1016/S1470-2045(18)30937-9
- Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. (2018) 359:1350–5. 10.1126/science.aar4060
- El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. . Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. (2017) 389:2492–502. 10.1016/S0140-6736(17)31046-2
- Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, et al. . Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. (2018) 19:940–52. 10.1016/S1470-2045(18)30351-6
- Zhu Y, Yang J, Xu D, Gao XM, Zhang Z, Hsu JL, et al. . Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade. Gut. (2019) 68:1653–66. 10.1136/gutjnl-2019-318419
- Kurebayashi Y, Ojima H, Tsujikawa H, Kubota N, Maehara J, Abe Y, et al. Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification. Hepatology. (2018) 68:1025–41. 10.1002/hep.29904
- Bilen MA, Martini DJ, Liu Y, Lewis C, Collins HH, Shabto JM, et al. . The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy. Cancer. (2019) 125:127–34. 10.1002/cncr.31778
- Scott AC, Dundar F, Zumbo P, Chandran SS, Klebanoff CA, Shakiba M, et al. TOX is a critical regulator of tumour-specific T cell differentiation. Nature. (2019) 571:270–4. 10.1038/s41586-019-1324-y
- Chew V, Lee YH, Pan L, Nasir NJM, Lim CJ, Chua C, et al. . Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma. Gut. (2019) 68:335–46. 10.1136/gutjnl-2017-315485
- Greten TF, Mauda-Havakuk M, Heinrich B, Korangy F, Wood BJ. Combined locoregional-immunotherapy for liver cancer. J Hepatol. (2019) 70:999–1007. 10.1016/j.jhep.2019.01.027
- Erinjeri JP, Fine GC, Adema GJ, Ahmed M, Chapiro J, den Brok M, et al. . Immunotherapy and the interventional oncologist: challenges and opportunities-a society of interventional oncology white paper. Radiology. (2019) 292:25–34. 10.1148/radiol.2019182326
- Takaki H, Imai N, Thomas CT, Yamakado K, Yarmohammadi H, Ziv E, et al. . Changes in peripheral blood T-cell balance after percutaneous tumor ablation. Minim Invasive Ther Allied Technol. (2017) 26:331–7. 10.1080/13645706.2017.1310737
- Shi L, Chen L, Wu C, Zhu Y, Xu B, Zheng X, et al. PD-1 blockade boosts radiofrequency ablation-elicited adaptive immune responses against tumor. Clin Cancer Res. (2016) 22:1173–84. 10.1158/1078-0432.CCR-15-1352
- Mizukoshi E, Yamashita T, Arai K, Sunagozaka H, Ueda T, Arihara F, et al. Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma. Hepatology. (2013) 57:1448–57. 10.1002/hep.26153
- Ayaru L, Pereira SP, Alisa A, Pathan AA, Williams R, Davidson B, et al. . Unmasking of alpha-fetoprotein-specific CD4(+) T cell responses in hepatocellular carcinoma patients undergoing embolization. J Immunol. (2007) 178:1914–22. 10.4049/jimmunol.178.3.1914
- Zerbini A, Pilli M, Laccabue D, Pelosi G, Molinari A, Negri E, et al. . Radiofrequency thermal ablation for hepatocellular carcinoma stimulates autologous NK-cell response. Gastroenterology. (2010) 138:1931–42. 10.1053/j.gastro.2009.12.051
- Smoragiewicz M, Bogaerts J, Calvo E, Marabelle A, Perrone A, Seymour L, et al. Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on methodology for the development of innovative cancer Therapies. Ann Oncol. (2018) 29:2175–82. 10.1093/annonc/mdy398
- Li X, Liang P. Immunotherapy for hepatocellular carcinoma following thermal ablation. J BUON. (2014) 19:867–71.
- Nishino M, Giobbie-Hurder A, Gargano M, Suda M, Ramaiya NH, Hodi FS. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res. (2013) 19:3936–43. 10.1158/1078-0432.CCR-13-0895
- Pan T, Xie QK, Lv N, Li XS, Mu LW, Wu PH, et al. Percutaneous CT-guided radiofrequency ablation for lymph node oligometastases from hepatocellular carcinoma: a propensity score-matching analysis. Radiology. (2017) 282:259–70. 10.1148/radiol.2016151807
- Mu L, Sun L, Pan T, Lyu N, Li S, Li X, et al. Percutaneous CT-guided radiofrequency ablation for patients with extrahepatic oligometastases of hepatocellular carcinoma: long-term results. Int J Hyperthermia. (2018) 34:59–67. 10.1080/02656736.2017.1318332
- Ahmed M, Solbiati L, Brace CL, Breen DJ, Callstrom MR, Charboneau JW, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria–a 10-year update. J Vasc Interv Radiol. (2014) 25:1691–705.e4. 10.1016/j.jvir.2014.09.005
- El Dika I, Khalil DN, Abou-Alfa GK. Immune checkpoint inhibitors for hepatocellular carcinoma. Cancer. (2019) 125:3312–9. 10.1002/cncr.32076
- Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, Lim HY, et al. Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC). J Clin Oncol. (2019) 37:abstr 4004 10.1200/JCO.2019.37.15_suppl.4004
- Nault JC, Sutter O, Nahon P, Ganne-Carrie N, Seror O. Percutaneous treatment of hepatocellular carcinoma: state of the art and innovations. J Hepatol. (2018) 68:783–97. 10.1016/j.jhep.2017.10.004
- Knox JJ, Cleary SP, Dawson LA. Localized and systemic approaches to treating hepatocellular carcinoma. J Clin Oncol. (2015) 33:1835–44. 10.1200/JCO.2014.60.1153
- Brooks ED, Chang JY. Time to abandon single-site irradiation for inducing abscopal effects. Nat Rev Clin Oncol. (2019) 16:123–35. 10.1038/s41571-018-0119-7
- Theelen W, Peulen HMU, Lalezari F, van der Noort V, de Vries JF, Aerts J, et al. Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT Phase 2 randomized clinical trial. JAMA Oncol. (2019) 5:1276–82. 10.1001/jamaoncol.2019.1478
- Xie C, Duffy AG, Mabry-Hrones D, Wood B, Levy E, Krishnasamy V, et al. . Tremelimumab in combination with microwave ablation in patients with refractory biliary tract cancer. Hepatology. (2019) 69:2048–60. 10.1002/hep.30482
- Zhang H, Hou X, Cai H, Zhuang X. Effects of microwave ablation on T-cell subsets and cytokines of patients with hepatocellular carcinoma. Minim Invasive Ther Allied Technol. (2017) 26:207–11. 10.1080/13645706.2017.1286356
- Dumolard L, Ghelfi J, Roth G, Decaens T, Macek Jilkova Z. Percutaneous ablation-induced immunomodulation in hepatocellular carcinoma. Int J Mol Sci. (2020) 21:4398. 10.3390/ijms21124398
- Duffy AG, Ulahannan SV, Makorova-Rusher O, Rahma O, Wedemeyer H, Pratt D, et al. . Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol. (2017) 66:545–51. 10.1016/j.jhep.2016.10.029
- Mu L, Pan T, Lyu N, Sun L, Li S, Xie Q, et al. . CT-guided percutaneous radiofrequency ablation for lung neoplasms adjacent to the pericardium. Lung Cancer. (2018) 122:25–31. 10.1016/j.lungcan.2018.05.004
- Saada-Bouzid E, Defaucheux C, Karabajakian A, Coloma VP, Servois V, Paoletti X, et al. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol. (2017) 28:1605–11. 10.1093/annonc/mdx178
Source: PubMed